Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma
Authors:
- Daegwang YooDYDaegwang Yoo
- Nayoung KimNKNayoung Kim
- Dae Wook HwangDHDae Wook Hwang
- Ki Byung SongKSKi Byung Song
- Jae Hoon LeeJLJae Hoon Lee
- Woohyung LeeWLWoohyung Lee
- Jaewoo KwonJKJaewoo Kwon
- Yejong ParkYPYejong Park
- Sarang HongSHSarang Hong
- Jong Woo LeeJLJong Woo Lee
- Kyungyeon HwangKHKyungyeon Hwang
- Dakyum ShinDSDakyum Shin
Open Access
- 22 June 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (6) , 1953
Abstract
Retrospective studies on the association between metformin and clinical outcomes have mainly been performed on patients with non-resectable pancreatic ductal adenocarcinoma and may have been affected by time-related bias. To avoid this bias, recent studies have used time-varying analysis; however, they have only considered the start date of metformin use and not the stop date. We studied 283 patients with type 2 diabetes and pancreatic ductal adenocarcinoma following pancreaticoduodenectomy, and performed analysis using a Cox model with time-varying covariates, while considering both start and stop dates of metformin use. When start and stop dates were not considered, the metformin group showed significantly better survival. Compared with previous studies, adjusted analysis based on Cox models with time-varying covariates only considering the start date of postoperative metformin use showed no significant differences in survival. However, although adjusted analysis considering both start and stop dates showed no significant difference in recurrence-free survival, the overall survival was significantly better in the metformin group (Hazard ratio (HR), 0.747; 95% confidence interval (CI), 0.562–0.993; p = 0.045). Time-varying analysis incorporating both start and stop dates thus revealed that metformin use is associated with a higher overall survival following pancreaticoduodenectomy in patients with type 2 diabetes and pancreatic ductal adenocarcinoma.Keywords
Funding Information
- Korean Health Technology R&D Project, Ministry of Health & Welfare (HI14C2640)
This publication has 46 references indexed in Scilit:
- Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer CellsFrontiers in Oncology, 2018
- Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancerCancer Causes & Control, 2018
- Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cellsPLOS ONE, 2018
- Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung CancerThe American Journal of the Medical Sciences, 2017
- Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancerMolecular Cancer, 2017
- Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progressionCancer Letters, 2017
- Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated MacrophagesPLOS ONE, 2015
- Metformin Suppresses Pancreatic Tumor Growth With Inhibition of NFκB/STAT3 Inflammatory SignalingPancreas, 2015
- Repurposing of Metformin and Aspirin by Targeting AMPK-mTOR and Inflammation for Pancreatic Cancer Prevention and TreatmentCancer Prevention Research, 2014
- Metformin and cancer: new applications for an old drugMedical Oncology, 2011